CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act
InfuSystem Holdings Inc. announced that the Centers for Medicare and Medicaid Services $(CMS)$ has added two electronic infusion pumps used by the company-ICU Medical's CADD-SolisTM and Eitan Medical's SapphireTM-to the list of products qualifying for separate payment under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. This CMS decision allows InfuSystem's current and potential Pain Management customers to receive separate reimbursement for these devices when used with covered surgical procedures, starting January 1, 2026, through December 31, 2027. The NOPAIN Act initiative is aimed at promoting non-opioid alternatives for pain management and reducing opioid use in postoperative care. The approval covers products from multiple manufacturers, not just InfuSystem.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-056364), on December 10, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。